All Posts Tagged With: "investing in biotech"
5 Fat-Dividend Paying Pharmacuetical Stocks
Given the gut-wrenching financial turmoil of the last year, many investors are looking for more secure ways of investing.
Floyd Brown says one way of doing this is to rethink the “boring” image of dividend-paying stocks. These stocks can offer great returns and a steady cash flow.
Floyd says there are five pharmaceutical companies offering outstanding dividend yields in a growing sector. And with most negative sentiment already priced into the stocks, downside risk is limited…
How to Successfully Invest in Biotech Stocks
Investing in biotech stocks can be incredibly rewarding, financially and personally, says Marc Lichtenfeld writing in Investment U. However, timing is crucial to success. Here, Marc walks investors through the three phases of the drug development process…
How to Profit from Biotech in Eastern Europe
It wasn’t long ago that we published several articles urging investors into the neglected biotech industry. Now Sara Nunnally over at Taipan Publishing says Central and Eastern Europe is a hot region for the sector right now. Big pharma is also looking to enter the rapidly growing market for generic drugs. And a popular way to establish a foothold in the region is through acquisitions of local firms.
Great Bargains in Ignored Biotech
There has been a lot of strong recommendations around biotech lately on Contrarian Profits.
Phase 1 Investor editor Rob Fannon recently wrote that biotech was one of the few market sectors to show positive returns as many other stocks were getting hammered. He sees great values in the sector.
There’s a good reason for this strength. A struggling economy won’t hurt biotech and medical as much as, say, an automaker, retailer, or restaurant chain… And biotech is one of the few industries showing solid sales growth.
Why the Smart Money Is in Biotech Stocks
As investors plowed into financial and housing stocks in the last few years, they forgot about the pharmaceutical industry, says Jim Nelson in Penny Sleuth.
But now that the party is over, biotech stocks are coming back in a big way. According to mutual-fund research firm Lipper, two biotech funds were amongst the top five best-performing vehicles in July - a dramatic reversal from June when commodities funds were leading the charge.
Big Pharma is buying up promising biotech companies in an effort to boost profit margins. This creates great opportunities for investors, and it’ only just the beginning…
How Nanotech Could Resurrect Small-Cap Pharma
The coming together of nanotech and biotech could resurrect the pharmaceutical market, says Patrick Cox in Penny Sleuth.
By using nanotech structures to modify existing drugs, small-cap pharma companies can sidestep the hefty costs and risks of new drug approval. This has traditionally been a major barrier to entry for start-ups. More importantly, early research has shown the altered drugs to be extremely effective against a broad range of serious diseases.
As new ventures approach IPO, they will create great investment opportunities. More from Patrick…
We Are Near a Stem Cell Solution for Heart Failure
Is it finally time to invest in stem-cell technology? Tech junkie Patrick Cox, writing in Penny Sleuth, thinks so.
The FDA recently banned stem cell company Geron Corporation (NASDAQ:GERN) from going ahead with trials of its spinal-cord therapy. But great transformational investors have always bought when the public has given up hope on new technologies.
It now looks like there might be a breakthrough in heart failure prevention, says Patrick. Although they won’t go on the record about it yet, leading researchers expect a breakthrough to occur in the next five years…
Biotech Sector Could Jump 25% on Roche-Genentech Deal
Swiss drug company Roche (OTC:RHHBY) may not get its hands on San Francisco-based biotech outfit Genenetech (NYSE:DNA) as quickly as it had hoped.
Genetech has formed a special committee of independent directors to evaluate the $89-a-share acquisition offer from Roche, which already owns 56 percent of the US biotech firm.
If the deal does go through it may be bad news for Roche and Genentech shareholders, according to Phase 1 Investor editor Rob Fannon in The Growth Stock Wire. But it would be good news for the biotech industry as a whole…
While I believe the bid is a bad move for Roche – and not a great proposal for Genentech shareholders – this mega-deal is actually good for the entire biotech industry… and its investors.
With Genentech gone, the top of the biotech food chain is empty. Many investors will be searching for new spots to park their biotech cash. And sector valuations are on the rise. Both major biotech indexes – the Nasdaq Biotech Index and AMEX Biotech Index – are up more than 7% in just a few weeks.
Small-cap biotechs are cheap right now. So I’d be willing to bet the sector could jump 25% or more in the coming months. And big-cap names like Biogen (NASDAQ:BIIB), Genzyme (NASDAQ:GENZ), and Elan (NYSE:ELN) have jumped to the top of Big Pharma’s short list of buyout candidates.
If you’re thinking of dabbling in the biotech sector, Roche’s bid for Genentech just may be the buy signal you’re waiting for.
Source: The Buy Signal You’ve Waited For
How to Play the Uptrend in Biotech With ETFs
Another strong play from medical stock expert Rob Fannon.
Rob says that although Big Pharma stocks are cheap right now - bellwether Pfizer (PFE) is cheaper than it’s ever been - drugmakers are racing off the side of a cliff.
This is because when patents expire drugmakers loose billions of dollars to generic manufacturers.
But biotech drugs can’t be copied easily. And the sector is in an uptrend. Rob recommends using a biotech ETF to play this trend.
How to Profit from the Fall of Big Pharma
Big Pharma is in trouble. Generic competition, patent expirations and slowing sales are all eating into profits.
So how can you turn a profit in this turbulent sector? By investing in contract research organisations, or CROs, says biotech expert Rob Fannon. When the big pharmaceutical companies outsource research to CROs they get paid whether or not the new drugs ever make it to market.
There’s another way to profit too - contract sales organizations, or CSOs. They’re another way for Big Pharma to outsource, but instead of doing research they sell.
Latest News
- Government Rescues Will Trigger a Bull Market in Gold11:22am CDT
- Natural Gas and Water Are the Investments of the Future2:41pm CDT
- J. Cristoph Amberger Says Buy Ford, Alon, GE, GM and GM Now11:00am CDT
- Get Ready for a Big Bear Market Bounce10:31am CDT
- Italy Shores Up Banking Sector as Recession Looms10:14am CDT
- Markets Plunge on Costly Credit, Paulson to Buy Bank Shares, IMF Warns of Global Recession10:09am CDT
- Why the Dow’s 40% Nosedive May Turn Into a Safe Landing10:01am CDT
- IBM Bucks Earnings Trend as Tech-Sector Stocks Trade Down to Bargain Levels9:55am CDT
- Andrew Snyder Says Potash Corp (POT) Still Has Further to Fall9:27am CDT
- Global Investing Roundups Friday, October 10th, 20089:14am CDT
- Early Indicators: Dow 5,000?8:18am CDT
- Chuck Butler: A New Trading Theme5:31pm CDT
- Damage Limitation in a Systemic Financial Meltdown3:55pm CDT
- Dow Plunges Below 9,000 Points3:39pm CDT
- Resource Stock Roundup Thursday, October 9, 20081:19pm CDT
- This Could Be Your Last Chance to Buy Gold Below $1,0001:16pm CDT
- Base Metals Savaged Again, but Aluminum Hanging In1:07pm CDT
- Sharp Drop in Gasoline Usage notes EIA, Crude Can’t Hang Onto $901:03pm CDT
- Central Banks Coordinate a Rate Cut, It May Not Be Enough12:57pm CDT
